Home » Stocks » AGE

AgeX Therapeutics, Inc. (AGE)

Stock Price: $1.16 USD -0.07 (-5.69%)
Updated May 13, 2021 1:30 PM EDT - Market open
Market Cap 47.42M
Revenue (ttm) 1.87M
Net Income (ttm) -10.87M
Shares Out 37.67M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.16
Previous Close $1.23
Change ($) -0.07
Change (%) -5.69%
Day's Open 1.23
Day's Range 1.16 - 1.28
Day's Volume 68,821
52-Week Range 0.67 - 3.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and opera...

1 month ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publi...

2 months ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research colla...

2 months ago - Business Wire

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,...

2 months ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting o...

4 months ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase health...

5 months ago - Business Wire

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human disease...

6 months ago - Business Wire

AgeX Therapeutics (AGE) stock is soaring higher on Thursday following news of that Juvenescence has a 50% stake in the company. The post AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 193% Today ...

7 months ago - InvestorPlace

ALAMEDA, Calif. & CARLSBAD, Calif.

Other stocks mentioned: LCTX
8 months ago - Business Wire

AgeX Therapeutics: Revolutionary Potential But Extremely Early

1 year ago - Seeking Alpha

About AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead... [Read more...]

Industry
Biotechnology
IPO Date
Nov 29, 2018
CEO
Michael West
Employees
6
Stock Exchange
NYSEAMERICAN
Ticker Symbol
AGE
Full Company Profile

Financial Performance

In 2020, AGE's revenue was $1.87 million, an increase of 8.10% compared to the previous year's $1.73 million. Losses were -$10.87 million, -10.61% less than in 2019.

Financial Statements